人工智慧設計的疫苗在人體試驗中展現潛力
AI-designed vaccine shows promise in human trials
Updated at: June 6, 2026 at 07:30 AM
在醫學界的一項突破性發展中，研究人員成功測試了首個完全由人工智慧設計的疫苗成分。
In a groundbreaking development for medical science, researchers have successfully tested the first vaccine component entirely designed by artificial intelligence.
這項創新研究由劍橋大學與 DIOSynVax 的科學家主導，重點在於一種稱為 pEVAC-PS 的「未來防禦」型疫苗。
Led by scientists at the University of Cambridge and DIOSynVax, this innovative study focuses on a 'future-proof' vaccine called pEVAC-PS.
與針對特定病毒株的傳統疫苗不同，這種通用候選疫苗使用了 AI 設計的「超級抗原」。
Unlike traditional vaccines that target a specific strain of a virus, this universal candidate uses an AI-designed 'super-antigen.'
這使得疫苗能夠引導免疫系統，不僅能識別當前的變異株，還能應對尚未出現的未來變異。
This allows the vaccine to prime the immune system to recognize not only current variants but also future mutations that haven't emerged yet.
在涉及 39 名志願者的第一期臨床試驗中，這種 DNA 疫苗透過無針噴射方式施打，證實安全且耐受性良好。
During a Phase I clinical trial involving 39 volunteers, the DNA vaccine was administered via a needle-free jet, proving safe and well-tolerated.
繼這些成功的初步結果後，研究人員正計劃進行更大規模的研究，以證實這些發現，並邁向全球大流行病準備的新時代。
Following these successful initial results, researchers are planning larger studies to confirm these findings and move closer to a new era of global pandemic preparedness.
